In a human clinical trial, repeated administration of an oligonucleotide–siRNA conjugate targeting SOD1 exhibited a favorable safety profile in six patients with SOD1-ALS.

Comprehensive, multinational validation of the PREVENT and SCORE2 cardiovascular risk scores, used in the United States and Europe, respectively, in 44 observational studies and 18 randomized trials, shows similar performance for the two risk scores and generally good performance across geographical regions.

As presented at the 2026 ESC Heart Failure Congress, in a phase 2 randomized trial in patients with heart failure with reduced left ventricular ejection fraction after myocardial infarction, treatment with CDR132L, an antisense oligonucleotide inhibitor of miR-132, was well tolerated but did not have a significant effect on measures of left ventricular structure or function.

As presented at the European Congress on Obesity, this randomized, placebo-controlled trial demonstrates that oral orforglipron, a nonpeptide GLP-1 receptor agonist, preserves weight loss and cardiometabolic benefits achieved with injectable GLP-1 receptor agonist therapies, making it a viable oral maintenance strategy.

Whole-slide histopathological images from 40 tissue types reveal morphological changes associated with aging, which, when paired with transcriptomic data from blood, are used to develop aging clocks that reflect tissue structural integrity and organ-level physiological fitness in health and disease.

In a multicenter, phase 2 trial, patients with treatment-naive locally advanced unresectable or metastatic triple-negative breast cancer were treated with the PD-1/vascular endothelial growth factor bispecific antibody ivonescimab plus chemotherapy, resulting in encouraging preliminary objective response rates, which support further testing in a large, randomized, phase 3 trial.

Circulating tumor DNA analyses in 44 patients with pancreatic cancer receiving the RAS(ON) multi-selective inhibitor daraxonrasib as part of a phase 1/2 trial, and preclinical translational modeling approaches, identify mechanisms of acquired resistance to monotherapy and inform potential combination strategies to overcome resistance.

A phylogenetic analysis of 22 genomes from the recent Bundibugyo virus outbreak in the Democratic Republic of the Congo and Uganda suggests the outbreak was caused by a new zoonotic spillover event.

In a phase 3 trial, obinutuzumab β significantly reduced relapse risk by 93.1% versus placebo in patients with AQP4-IgG⁺ NMOSD, improved clinical and MRI outcomes, showed manageable safety and demonstrated sustained efficacy with no relapses during extended follow-up.

Analysis of longitudinal blood samples shows that CD19 CAR T cells can be detected at least 10 years after treatment in patients with lymphoma, with deeper profiling from a single patient showing that these CAR T cells have a dominant double-negative activated effector-memory-like phenotype.

In this Comment, we outline the Nordic AI-Health Initiative platform, built on unique large-scale longitudinal and multimodal health data sets from across the region. The platform is designed to enable secure, regulation-compliant access and to deliver generalizable models for responsible AI-driven discovery in medicine.

A new generation of clinical decision support tools is moving into practice, reshaping how evidence is generated, evaluated and used.

Automated visual evaluation (AVE) could be transformative for cervical cancer screening in low-resource settings. However, AVE research has yet to yield robust clinical tools. Frugal approaches are needed that emphasize efficient, multimodal models, explainable outputs, local calibration and evaluation in real-world screening workflows.

Once seen as a symptom, disrupted sleep is emerging as a modifiable driver of chronic illness. Drugmakers are targeting sleep pathways to reshape chronic disease biology, from pain to depression.